【Product name】Tagrisso
[English common name]Ochinib
[Chinese common name]Ochinib
[English name]
[Chinese other name]
[Indications] This product is suitable for the development of disease in the past or after treatment with the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), and confirmed by the detection of the presence of EGFR T790M mutation positive local late or metastasis SexNon-small cell lung cancer (NSCLC)Treatment for adult patients.
[Usage and Dosage] This product should be used by a doctor who has experience in anti-tumor treatment.
Before using this product to treat locally advanced or metastatic NSCLC, it is first necessary to determine the status of the EGFR T790M mutation. A well-validated test should be used to determine the presence of the EGFR T790M mutation for treatment with this product.
dose
The recommended dose of this product is 80mg per day until the disease progresses or the intolerable toxicity occurs.
If you miss this product once, you should take this product, unless the next time you take the drug within 12 hours.
This product should be taken at the same time every day, either at mealtime or on an empty stomach.
Dose adjustment
The medication may be suspended or reduced depending on the individual's safety and tolerability. If a reduction is required, the dose should be reduced to 40 mg once daily.
Special population
There is no need to adjust the dose for the patient's age, weight, sex, race and smoking status.
Liver damage
Mild liver function impairment (total bilirubin < upper limit of normal (ULN) and aspartate aminotransferase (AST) up to 1 to 1.5xULN; or total bilirubin up to 1 to 1.5xULN, AST is not limited) patients do not need dose adjustment, However, such patients should still use this product with caution. The safety and efficacy of this product in patients with moderate to severe liver damage is not clear. This product is not recommended for patients with moderate to severe liver damage before obtaining more information. (See [Pharmacokinetics]).
Renal impairment
Patients with mild to moderate renal impairment do not need to adjust the dose when using this product. There is limited data on the use of this product in patients with severe renal impairment. The safety and efficacy of end-stage renal disease (creatinine clearance (CLcr) <15 mL/min calculated by Cockcroft and Gault equations) or patients undergoing dialysis is unclear. This product should be used with caution in patients with severe or end-stage renal impairment (see [Pharmacokinetics]).
Method of administration
This product is for oral use. This product should be taken in whole tablets and water, and should not be crushed, cut or chewed.
If the patient is unable to swallow the drug, the tablet can be dissolved in 50 mL of carbonate-free water. The tablets should be placed in water without crushing and stirred directly until dispersed for rapid swallowing. Then add half a cup of water to ensure no residue in the cup, then drink quickly. No other liquid should be added.
When feeding through a gastric tube is required, the treatment can be carried out in the same manner as described above, except that 15 mL of water is initially dissolved in the drug, and 15 mL of water is used in subsequent washing of the residue. This 30 mL of fluid should be fed as directed by the nasogastric tube manufacturer and rinsed with an appropriate amount of water. These solutions and residuals should be taken within 30 minutes after the tablets are added to the water.
[Storage]Store below 30 °C.
[Tips] Some of the information on this site comes from the Internet and is only used internally by pharmacists or medical staff. It is not a substitute for doctors to diagnose face to face. Please consult a professional pharmacist for specific medications. Please refer to the actual product manual or the actual product for the product content.
简体中文